NASDAQ · INMD
Healthcare · Medical - Devices
$14.91
Down-$0.10 (-0.67%)
Updated Sep 9, 2026, 12:15 AM
SID Score
5.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 19 trading sessions · Daily adjusted prices
INMD closed at $14.91 after 19 trading sessions, down 1.52% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $14.79 | $14.94 | $14.7719 | $14.91 | 449.39K |
| Sep 3, 2026 | $14.99 | $15.04 | $14.77 | $14.84 | 523.01K |
| Sep 2, 2026 | $15.01 | $15.10 | $14.92 | $14.95 | 412.75K |
| Sep 1, 2026 | $14.99 | $15.20 | $14.93 | $15.03 | 799.93K |
| Aug 31, 2026 | $14.85 | $14.98 | $14.7501 | $14.96 | 698.84K |
| Aug 28, 2026 | $14.88 | $14.94 | $14.83 | $14.85 | 456.67K |
| Aug 27, 2026 | $14.87 | $14.9295 | $14.78 | $14.84 | 322.48K |
| Aug 26, 2026 | $15.00 | $15.015 | $14.90 | $14.93 | 319.18K |
| Aug 25, 2026 | $15.10 | $15.16 | $15.005 | $15.03 | 298.73K |
| Aug 24, 2026 | $15.09 | $15.17 | $15.025 | $15.10 | 425.02K |
| Aug 21, 2026 | $14.92 | $15.11 | $14.92 | $15.06 | 304.45K |
| Aug 20, 2026 | $14.95 | $15.00 | $14.8535 | $14.92 | 433.2K |
| Aug 19, 2026 | $15.02 | $15.13 | $14.945 | $15.04 | 491.75K |
| Aug 18, 2026 | $15.06 | $15.09 | $14.94 | $14.99 | 375.9K |
| Aug 17, 2026 | $15.13 | $15.15 | $14.96 | $15.02 | 548.99K |
| Aug 14, 2026 | $15.25 | $15.31 | $15.10 | $15.15 | 350.55K |
| Aug 13, 2026 | $15.30 | $15.38 | $15.085 | $15.20 | 347.69K |
| Aug 12, 2026 | $15.02 | $15.28 | $15.02 | $15.23 | 358.41K |
| Aug 11, 2026 | $15.21 | $15.34 | $15.12 | $15.14 | 355.43K |
The latest Smart Investors Daily articles mentioning INMD.
INMD research
Company profile and research snapshot.
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions in the United States. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF and Morpheus8. The majority of its revenue comes from the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 7, 2026 | Barclays | Overweight | — |
| May 7, 2026 | Baird | Neutral | — |
| Dec 17, 2025 | Canaccord Genuity | Hold | — |
| Nov 6, 2025 | UBS | Neutral | — |
| Oct 10, 2025 | Canaccord Genuity | Hold | — |
No generated briefing is available yet.
Benzinga · Aug 11, 2026
https://www.sec.gov/Archives/edgar/data/1742692/000117891326004040/zk2635934.htm
ChartMill · Aug 5, 2026
InMode Q2 revenue of $95.6M matches estimates, EPS beats at $0.35; shares slip 2.5% as growth stays flat.
Yahoo · Aug 5, 2026
InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the second quarter of 2026.
Benzinga · Aug 5, 2026
InMode (NASDAQ:INMD) lowers FY2026 Adj EPS guidance from $1.33-$1.38 to $1.29-$1.34 vs $1.34 analyst estimate. Affirms FY2026 sales outlook from $365.000 million-$375.000 million to $365.000 million-$375.000 million vs
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning INMD.
